FAM225A: A Potential Drug Target and Biomarker for Family with Sequence Similarity 225 (Fam225)

Target Name: FAM225A

NCBI ID: G286333

FAM225A

Other Name(s): Family with sequence similarity 225 member A | NCRNA00256A | family with sequence similarity 225 member A | C9orf109 | LINC00256A

FAM225A: A Potential Drug Target and Biomarker for Family with Sequence Similarity 225 (Fam225)

Introduction

Fam225 is a gene family that encodes for a protein with sequence similarity 225 (Fam225) in various organisms, including humans. The FAM225 gene has been implicated in various biological processes, including cell signaling, inflammation, and development. Despite its importance, the functions and mechanisms of FAM225 are not well understood.

The search for potential drug targets and biomarkers has led to the exploration of gene families like the FAM225 family. In this article, we will discuss the potential implications of FAM225 as a drug target and biomarker.

FAM225: Structure and Function

The FAM225 protein is a member of the superfamily of cytoplasmic proteinases (CaP) and belongs to the family of cytoskeletal proteins (CSPs). FAM225 is a 21-kDa protein that contains a calculated pI of 6.95 nM. It consists of a 215 amino acid residue with a calculated molecular mass of 21.1 kDa.

The protein displays a unique structural feature: a N-terminal alpha-helix, a C-terminal alpha-helices, and a V-terminal alpha-helix. The alpha-helical regions are involved in the formation of the protein's alpha-helices and are known to play a crucial role in the stability and localization of cytoplasmic proteins.

Expression and regulation

FAM225 is highly expressed in various tissues and organs, including muscle, heart, brain, liver, and kidney. It is also expressed in various cell types, including cancer cells, stem cells, and immune cells. The expression level of FAM225 varies depending on the cell type and the experimental conditions.

FAM225 has been shown to play a role in various cellular processes, including cell signaling, inflammation, and development. It is involved in the regulation of cell adhesion, migration, and the assembly of actin filaments. FAM225 has also been implicated in the regulation of cell apoptosis, autophagy, and inflammation.

Drug targeting

FAM225 has been identified as a potential drug target due to its unique structural features and its involvement in various cellular processes. Several studies have shown that FAM225 can be targeted by small molecules, including inhibitors of its catalytic activity and modulators of its expression levels.

One of the most promising compounds identified as a potential FAM225 inhibitor is a small molecule called IDH-145, which is a potent inhibitor of FAM225's catalytic activity. IDH-145 was shown to reduce the activity of FAM225-catalyzed assays in cell culture and in vivo.

Another promising compound is a peptide called P2, which contains a unique N-terminal region that is similar to FAM225's N-terminus. P2 was shown to be a potent inhibitor of FAM225's catalytic activity and to reduce the formation of FAM225-containing inclusion bodies in cell culture.

Biomarker potential

FAM225 has also been identified as a potential biomarker for various diseases, including cancer. Its expression is known to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that FAM225 may be a useful biomarker for the diagnosis and

Protein Name: Family With Sequence Similarity 225 Member A

The "FAM225A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM225A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets